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Abstract Background Since the launch of imatinib,
chronic myeloid leukaemia has become a chronic condi-
tion requiring costly long-term treatment. Emerging evi-
dence from several short-term studies has raised concerns
on the detrimental clinical outcomes and waste of
resources associated with poor adherence to imatinib.
Objective This study aims to evaluate the effects of long-
term imatinib adherence on clinical treatment responses
and mortality. Setting This retrospective cohort study was
conducted in a medical centre in southern Taiwan.
Method Chronic myeloid leukaemia patients who were
prescribed for more than 1 month of imatinib were iden-
tified and their medical charts were reviewed from the
first date of imatinib prescription to the last date of
medical record or upon patients’ death. Patients’ basic
characteristics, imatinib prescriptions, results of laboratory
tests, episodes of imatinib-related side effects and mor-
tality rate were recorded. Main outcome measure Partic-
ipants’ basic characteristics, medication possession ratio
and their mortality rate; the association between the
medication possession ratio and treatment responses.
Results Of the 119 included patients, the mean follow-up
time was 3.9 ± 2.9 patient-years and the mean medication
possession ratio was 89.7 %. At the 18th month of i-
matinib treatment, 67.2, 54.3 and 34.5 % patients
achieved complete cytogenetic, major molecular and
complete molecular responses, respectively. There was a
significant difference in the 4-year survival rate between
the adherence (n = 87) and non-adherence (n = 32)
groups (91 vs. 72 %; p = 0.0076). Logistic regression
analysis revealed that imatinib adherence was the only
factor that significantly influenced the 18th month com-
plete cytogenetic response [odds ratio (OR) 11.6; 95 %
confidence interval (CI) 1.7, 114.7; p = 0.0131] and
major molecular response (OR 5.1; 95 % CI 1.1, 26.8;
p = 0.0351). Cox regression analysis demonstrated that a
medication possession ratio greater than 90 % signifi-
cantly reduced the mortality risk (hazard ratio 0.1; 95 %
CI 0.01, 0.60; p = 0.0118). Conclusion Chronic myeloid
leukaemia patients’ long-term adherence to imatinib is
significantly associated with the 18th month treatment
responses including the cytogenetic response, molecular
response and the long-term survival rate in clinical
practice.
Keywords Chronic myeloid leukaemia  Imatinib 
Persistence - Taiwan  Medication possession ratio
Impact of findings on practice statements
• Imatinib users in Taiwan achieving early-stage treat-
ment targets were more likely to have better long-term
outcomes.
• Multiple therapy switches in Taiwanese imatinib users
seem to lead to poor adherence and outcomes.
T.-C. Chen  Y.-B. Huang
Graduate Institute of Clinical Pharmacy, Kaohsiung Medical
University, Kaohsiung, Taiwan
L.-C. Chen (&)
Division for Social Research in Medicines and Health, School of
Pharmacy, University of Nottingham, East Drive, University
Park, Nottingham NG7 2RD, UK
e-mail: li-chia.chen@nottingham.ac.uk
C.-S. Chang
Division of Hematology-Oncology, Department of Internal
Medicine, Kaohsiung Medical University Hospital, Kaohsiung
Medical University, Kaohsiung, Taiwan
123
Int J Clin Pharm (2014) 36:172–181
DOI 10.1007/s11096-013-9876-7
Introduction
Chronic myeloid leukaemia (CML) is a bone marrow stem
cell disorder caused by mutated chromosome (Philadelphia
chromosome) and is characterised by the increased growth
of premature white cells [1]. The annual incidence rate of
CML was approximately 1–2 per 100,000 people, and
accounted for 15–20 % of all adult leukaemia patients in
Western countries. It occurs in all age groups but is more
prevalent with the middle-aged and the elderly, and is
slightly more common in males than females [2]. Most
CML patients are diagnosed at the chronic phase with
relatively mild symptoms, but as the disease progresses to
the accelerated and blast phases, hyperleukocytosis,
abnormality platelet level, and other crisis systematic
symptoms often lead to mortality [3].
Traditional treatments for CML include chemotherapy
(such as cytarabine, hydroxyurea), interferon, and hema-
topoietic stem cell transplantation (HSCT). Although the
latter is still the only curative option, the use of this is
limited due to the lack of human leukocyte antigen mat-
ched donor and the potential chronic graft-versus-host
disease [4]. After the launch of tyrosine kinase inhibitors
(TKIs, such as imatinib), interferon and chemotherapy are
used less frequently due to the limited efficacy and the
intolerable adverse effects [4], and hydroxyurea is only
used to control leukocytosis.
Since the launch of imatinib, the first TKI soon becomes
the first-line of treatment for CML due to the advantages of
low toxicity, the route of oral administration and the sig-
nificant improvement in the survival rate (95.2 %) as
demonstrated in clinical trials [5]. In the last decade, this
innovative pharmacotherapy has turned CML from a pro-
gressive disease with a high mortality rate into a chronic
condition. The long-term use of expensive imatinib has
also resulted in the increasing cost of CML treatment, and
CML has now become one of the most costly diseases [6].
In relation to the increasing therapeutic cost, ensuring
medicine adherence and optimal disease control have
become challenging issues in the long-term utilisation of
imatinib. Guidelines from the National Comprehensive
Cancer Network (NCCN) suggest that monitoring indictors
for long-term TKI efficacy at the 3rd, 6th, 12th and
18th month of this treatment (Table 1) [7]. However, since
no indicator has been established after the 18th month of
treatment, a patients’ survival is regarded the only outcome
measure [8].
Emerging evidence has raised concern about the detri-
mental effects associated with poor adherence to oral
anticancer drugs, including imatinib [9]. This could worsen
treatment outcomes, resulting in treatment failure and
substantial waste of healthcare resources [10]. However,
previous studies have only evaluated adherence to imatinib
on chronic-phase and treatment-naı¨ve CML patients who
were predominately recruited from Western countries [11]
and followed for less than 1 year. [10–13]. Therefore,
evidence for the association between long-term adherence
to imatinib and CML survival in Asian populations is still
limited.
In Taiwan, the incidence of CML was 1.2 case per
100,000 population from 1998 to 2007, and the mean age
of diagnosis was 55.7 years [14]. CML treatment is
delivered under the coverage of the Taiwan National
Health Insurance (NHI), and imatinib and other second-
generation TKIs (including dasatinib and nilotinib) were
available for CML patients from 2003 to 2008 respec-
tively. According to the NHI reimbursement policy, i-
matinib is the first-line of treatment for all patients
Table 1 Definitions of tyrosine kinase inhibitor treatment responses









6th A reduction of Ph-positive cells to 1–34 %
Complete cytogenetic response
(CCyR)
12th The disappearance of Ph-positive cells (0 % cells with Ph-positive)
Complete cytogenetic response
(CCyR)*
18th The disappearance of Ph-positive cells (0 % cells with Ph-positive)
Complete molecular response
(CMR)
18th Undetectable BCR-ABL transcripts (a fusion gene indicating the mutation point of Ph)
Major molecular response (MMR) 18th A 3-log reduction in transcript level
These definitions are adopted from the National Comprehensive Cancer Network (NCCN) guideline [7]. The standard treatment target at
18th month can achieve CCyR, but CMR and MMR are regarded as better outcomes
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including those diagnosed at chronic, accelerated or blast
phase, and dasatinib and nilotinib are only reserved for
patients who are resistant or intolerant to imatinib.
Studies on imatinib utilisation and the impacts of
adherence to TKIs on CML control in Taiwan are still
very limited.
Aim of the study
This study aimed to measure and evaluate the association
between long-term imatinib adherence and the treatment
outcomes in a Chinese population.
Methods
Study design and cohort
This retrospective cohort study was conducted from May
2011 to March 2012 in a medical centre in southern Taiwan
after the ethics approval from the Institutional Review
Board of the research centre (reference: IRB-20110160)
was granted. This hospital, together with two other medical
centres, offer tertiary care for approximately 3.3 million
inhabitants in southern Taiwan, and there are around 6,000
outpatients visiting the research centre daily. At the time of
research, it was estimated that around 120 CML patients
have visited the research centre for treatment.
Hospital electronic administration records and patients’
medical records were used as the research data source.
Patients who were diagnosed as Philadelphia chromosome
positive (Ph-positive) CML and prescribed imatinib for
more than 1 month were identified from the hospitals’
electronic administration records from January 2000 to
October 2011. Patients’ medical charts were reviewed by a
researcher from the first imatinib prescription date (the
index date) to either the data collection date or the date of
the last medical record. The duration from the index date to
the end of follow-up is defined as the ‘follow-up period’.
Data collection
A data collection form for recording patients’ demo-
graphics, disease characteristics, imatinib utilisation and
clinical outcome indicators was designed according to
existing literature and oncology expert opinions, and it was
piloted on three patients’ charts to ensure its feasibility.
The piloting results are also included in the analysis.
Patients’ demographics (age and gender), Charlson
comorbidity index [15, 16], records of CML treatments
prior to imatinib (interferon, HSCT or second-generation
TKIs) and the disease stage when imatinib was initiated
were collected. Patients’ imatinib prescription details were
followed from the index date to the last prescription record.
Other treatments such as HSCT or second-generation TKIs
given during the follow-up period were also recorded.
All laboratory test results of biological markers for
hematologic, cytogenetic and molecular responses were
recorded as the clinical indicators for disease prognosis.
Laboratory tests associated with imatinib-related adverse
effects, including white blood cell count, platelet, gluta-
mate oxaloacetate transaminase, glutamic pyruvic trans-
aminase, and bilirubin levels were also recorded. Imatinib-
related adverse effects, i.e. leukocytopenia, thrombocyto-
penia and hepatotoxicity were defined following the NCCN
guideline [7], and the severity was graded according to the
Common Toxicity Criteria developed by the National
Cancer Institute of the National Institutes of Health in the
US.
Adherence and outcome measures
The primary outcome measures include imatinib-related
adherence, clinical outcomes and mortality. The medica-
tion possession ratio (MPR) was obtained by dividing each
patient’s ‘total number of days of supply’ of imatinib
prescriptions by the ‘prescription duration’ as a proxy for
adherence, and a conventional cut-off of less than 90 %
was used as a synonym for non-adherence [11]. For
patients who never received HSCT or second-generation
TKIs prior to imatinib, their mortality rate and the four
treatment response criteria (Table 1) recommended by the
NCCN [7] were used to measure the clinical outcomes.
Data analysis
Participants’ basic characteristics, MPR, treatment
response and imatinib-related side effects are presented in
descriptive statistics. The imatinib treatment pathway of
the study cohort is presented in proportion according to
different therapies, imatinib utilisation patterns (switched),
and follow-up endpoints. Kaplan–Meier analysis and Log-
rank tests were used to compare mortality rate between
adherence and non-adherence groups for patients who
never received HSCT or other second-generation TKIs
prior to imatinib.
For patients who had biological markers related to
complete cytogenetic response (CCyR), major molecular
response (MMR) and complete molecular response (CMR)
recorded at the 18th month, covariates associated with
achieving treatment responses at the 18th month were
evaluated using a logistic regression model. Binary
covariates which were evaluated in the model included:
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whether patients younger than 50 years were male, whether
patients’ CCI was equalled to 0, whether patients were at
chronic phase when imatinib started, whether patients had
an MPR [ 90 % and whether patients had imatinib related-
side effects. The regression results were presented in odds
ratio (OR) and 95 % confidence interval (95 % CI). In
addition, Cox regression was used to test the association
between covariates and the mortality rate in follow-up
period, and the results were presented in hazard ratio (HR)
and 95 % CI.
Furthermore, various cut-off points of MPR were used
to test the impacts of non-adherence definitions [17]. The
significance level was set at p \ 0.05. All analyses were




Overall, 119 patients with a total follow-up time of 469.2
patient-years (mean 3.9 ± 2.9 years) were included in this
study. The majority of the patients were in their middle age
(mean 45.7 ± 16.9 years), males (n = 70, 58.8 %), treated
with imatinib from the chronic phase of CML (n = 92,
77.3 %) without major co-morbidity (Table 2).
Prior to imatinib treatment, 39 (32.8 %) patients had
received other treatments for CML, and the majority
received interferon (n = 37, 31.1 %); only a few patients
received HSCT (n = 2, 1.7 %) and second-generation
TKIs (n = 1, 0.8 %). In addition, 79 (66.4 %) patients had
Table 2 Characteristics of
patients






ratio (MPR) C 90 %; non-
adherence: patients whose
imatinib medication possession
ratio (MPR) \ 90 %
Characteristic Total Adherence(d) p value
Adherence Non-adherence
Number of patients (%) 119 87 (73.1 %) 32 (26.9 %)
Gender
Male 70 (58.8 %) 53 (60.9 %) 17 (53.1 %) 0.4437
Age
Mean ± SD(a) 45.7 ± 16.9 45.3 ± 16.9 46.7 ± 17.4 0.6923
Median (Q1, Q3) 46 (31.5, 58.8) 44 (31, 58.3) 48.5 (33.3, 60.8)
Over 50 years 47 (40.5 %) 36 (41.9 %) 11 (36.7 %) 0.6178
Follow-up time (year)
Total (patient-years) 469.2 364.3 104.9
Mean ± SD(a) 3.9 ± 2.9 4.2 ± 2.9 3.3 ± 2.8 0.1463
Median (Q1, Q3) 3 (1.5, 6) 3.8 (1.6, 6.3) 2.1 (1.5, 5.2)
CCI score (%)(b) 0.6800
0 78 (65.5 %) 57 (65.5 %) 21 (65.6 %)
1 29 (24.4 %) 20 (23 %) 9 (28.2 %)
2 9 (7.6 %) 8 (9.2 %) 1 (3.1 %)
3 3 (2.5 %) 2 (2.3 %) 1 (3.1 %)
Disease stages at imatinib initiating 0.6728
Chronic phase 92 (77.3 %) 68 (78.2 %) 24 (75.0 %)
Accelerated phase 21 (17.6 %) 14 (16.1 %) 7 (21.9 %)
Blast phase 6 (5.1 %) 5 (5.7 %) 1 (3.1 %)
Prior treatments
Interferon 37 (31.1 %) 21 (24.1 %) 16 (50.0 %) 0.0069*
HSCT(c) 2 (1.7 %) 2 (2.3 %) 0 0.3843
Second-generation TKIs 1 (0.8 %) 1 (1.1 %) 0 0.5425
Hydroxyurea 79 (66.4 %) 55 (63.2 %) 24 (75 %) 0.2277
Prior treatment-naı¨ve patients 30 (25.2 %) 24 (28.6 %) 6 (18.8 %) 0.3147
Time to initiate imatinib initiating (year)
Mean ± SD(a) 0.7 ± 1.7 0.6 ± 1.4 1.3 ± 2.5 0.0845
Median (Q1, Q3) 0.1 (0.01, 0.4) 0.1 (0.01, 0.2) 0.1 (0.01, 2.1)
Imatinib-related side effects
Grade II leukocytopenia 22 (18.5 %) 10 (11.5 %) 12 (37.5 %) 0.0012*
Grade II thrombocytopenia 49 (41.2 %) 29 (33.3 %) 20 (62.5 %) 0.0042*
Grade II hepatotoxicity 11 (9.2 %) 7 (8 %) 4 (12.5 %) 0.7540
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received hydroxyurea for controlling leukocytosis. There-
fore, there were only 30 (25.2 %) treatment naı¨ve patients.
During the follow-up period, 22 (18.5 %), 49 (41.2 %) and
11 (9.2 %) patients experienced Grade II leukocytopenia,
Grade II thrombocytopenia and hepatotoxicity respectively
(Table 2).
There was no significant difference in patients’ character-
istics between the adherence and non-adherence groups, but a
higher proportion of non-adherence patients who were found
to have received interferon (24.1 vs. 50 %, p = 0.0069) prior
to imatinib treatment and experienced grade II leukocytopenia
(11.5 vs. 37.5 %, p = 0.0012) and thrombocytopenia (33.3
vs. 62.5 %, p = 0.0042) (Table 2).
Imatinib utilisation pattern
Of the 119 patients, 17 (14.3 %) patients died and 26 (21.8 %)
patients missed the follow-up appointments (stopped visiting
the research site), whereas 56 patients (47.1 %) were receiv-
ing imatinib and 20 (16.8 %) patients discontinued imatinib
and switched to second-generation TKIs or HSCT at the end of
the follow-up. Overall, 87 (73.1 %) patients only used i-
matinib and 32 (26.9 %) patients had switched to other
treatments (HSCT or other TKIs) during the study period. For
the 32 patients who had switched from imatinib to other
treatments, a small number of patients (n = 5, 15.6 %)
switched back to imatinib treatment, but only 2 (40.0 %) of
those active patients kept using imatinib by the end of the
follow-up (Fig. 1).
Adherence to imatinib
The median imatinib prescription duration was 2.1 (range
0.2–11.1) years. Most patients (n = 57, 47.9 %) used
imatinib for less than 2 years, while 35 (29.4 %) and 10
(8.4 %) patients used imatinib for over 5 and 9 years,
respectively. Patients were generally adherent to imatinib,
the median MPR of the 119 patients was 98.3 % (range
12.6–100 %), and it was more than 90 % for 87 (73.1 %)
patients and 100 % for 41 (34.5 %) patients. However,
there was still a small proportion of patients (n = 12,
10.1 %) whose MPR was lower than 60 % (Fig. 2).
Treatment responses and survival rate
The short-term response to imatinib treatment for the 116
patients who never received HSCT or second-generation
TKIs prior to imatinib were generally satisfactory, 113
(97.4 %), 76 (65.5 %) and 75 (64.7 %) patients achieved
ChR, PCyR and CCyR at the 3rd, 6th and 12th month of
imatinib treatment, respectively. At the 18th month of i-
matinib treatment, 78 (67.2 %), 63 (54.3 %) and 40
(34.5 %) patients achieved CCyR, MMR and CMR
(Fig. 3). Sixteen of the 116 patients died during the follow-
up period and the overall 4-year survival rate was 86.2 %.
There was a significant difference in terms of the 4-year
survival rate between the adherence (76/83; 91 %) and
non-adherence group (24/33; 72 %) (p = 0.0076) (Fig. 4).
Adherence associated treatment responses
and mortality
The median MPR for the 87 patients who had results of
biological markers for CCyR, MMR and CMR recorded
within 18 months of imatinib treatment was 99.4 % (range
10.4–100 %). Logistic regression analysis revealed that i-
matinib adherence (i.e. MPR [ 90 %) was the only factor
that might have significantly influenced the 18th month
Loss follow-up (n=5, 15.6%) or die (n=4, 12.5%) 




Switch to others* (n=1, 25.0%)






Continue imatinib (n=1, 50.0%) 











Continue imatinib (n=54, 45.4%) 










Fig. 1 Chronic myeloid
leukaemia patients’ utilisation




(HSCT) or other tyrosin kinase
inhibitors (TKIs). The dot
rectangle highlights the
multiple switches of imatinib
treatment
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CCyR and MMR rates, despite the wide range of ORs (11.6;
95 % CI 1.7, 114.7; p = 0.0131 and 5.1; 95 % CI 1.1, 26.8;
p = 0.0351). None of the covariates found associated with
the CMR rate at the 18th month of imatinib treatment. Fur-
thermore, results of Cox regression demonstrated that an
MPR greater than 90 % could significantly reduce the mor-
tality risk (HR 0.1; 95 % CI 0.01, 0.6; p = 0.0118). On the
contrary, it was found that experience of grade II thrombo-
cytopenia was associated with increased mortality (HR: 8.1,
95 % CI 1.4, 65.9; p = 0.0223).
The sensitivity analysis assessing various cut-off points
of MPR to define adherence indicated that adherence to
imatinib was associated with a higher proportion of
patients achieving CCyR at the 18th month when adher-
ence was defined as MPR over 90, 85 and 80 %, with OR
at 11.6 (95 % CI 1.7, 114.7; p = 0.0131), 11.9 (95 % CI
1.7, 113.1; p = 0.0140) and 13.2 (95 % CI 1.9, 122.6;
p = 0.0102) respectively. Similarly, those MPR cut-offs
were associated with a higher proportion of patients











































Medication possession ratio (%) rank
Prescription duration (patient-years)
Duration of supply (patient-years)
Number of patients
Fig. 2 Number of patients and
patient-years in each medication
possession ratio rank
12-month CCyR (+) 
(n=72, 94.7%) 
Loss follow-up (n=2, 9.5%) 
Loss follow-up (n=15, 13.3%) or die (n=1, 0.9%) 
12-month CCyR (-) 
(n=4, 5.3%) 
6-month PCyR (-) (n=2, 66.7%), loss follow-up at the 12th




Die (n=2, 2.8%) 
18-month CMR (+) (n=39, 55.7%) 
18-month CCyR (+) (n=11, 15.7%) 
18-month MMR (+) (n=20, 28.6%) 
12-month CCyR (+) 
(n=3, 14.3%) 
12-month CCyR (-) 
(n=16, 76.2%) 
6-month PCyR (+) 
(n=76, 67.3%) 
6-month PCyR (-) 
(n=21, 18.6%) 
3-month ChR (+) 
(n=113, 97.4%) 
3-month ChR (-) 
(n=3, 2.6%) 
18-month CCyR (+) (n=1, 25.0%) 
18-month CCyR (-) (n=2, 50.0%) 
18-month MMR (+) (n=1, 25.0%) 
18-month CCyR (+) (n=1, 33.3%) 
18-month CMR (+) (n=1, 33.4%) 


















18-month CCyR (+) (n=2, 6.3%) 
18-month CCyR (-) (n=13, 81.3%) 
18-month MMR (+) (n=1, 12.5%) 
Fig. 3 Proportion of imatinib
users achieving treatment
responses at various points up to
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CI 1.1, 26.8; p = 0.0351), 6.8 (95 % CI 1.2, 45.4;
p = 0.0281) and 8.8 (95 % CI 1.5, 63.9; p = 0.0151),
respectively. However, adherence was not associated with
the CMR rate at the 18th month regardless of the cut-off
points to define adherence. Adherence was associated with
a lower mortality rate when MPR is over 95 % (HR 0.1,
95 % CI 0.01, 0.6; p = 0.0118) and 90 % (HR 0.1; 95 %
CI 0.01, 0.6; p = 0.0118) (Fig. 5).
Discussion
This study found that most CML patients were highly
adherent to imatinib treatment based on the MPR measure,
and achieved CCyR at the 18th month; but a minority
(4 %) of patients presented a problematic pattern of mul-
tiple switches. Regardless of patients’ initial disease phase,
adherence to imatinib was associated with a better survival
rate and most clinical indicators. The interruptions and
patients’ treatment pathway examined in this study reveal
the complex and multifaceted nature of CML treatment.
Medicine adherence has been reported [18] to be asso-
ciated with patients [19], social and medical support, and
medication related factors [20]. The use of imatinib for
treating CML is likely to be interrupted for various clinical
reasons (e.g. efficacy, safety, and tolerability) or accessi-
bility and affordability problems. As imatinib is covered by
the NHI in Taiwan, affordability is a less important con-
cern. The higher proportion of patients in the non-adher-
ence group who received interferon prior to imatinib and
experienced imatinib-related side effects (Table 2) indi-
cated that patients’ pre-treatment condition and intolerance
to imatinib-related side effects are the main reasons of non-
adherence to imatinib.
Previous literature has suggested that about 6 % of CML
patients were intolerant to the side effects of imatinib [21].
Dose adjustment, temporal interruption, and switching to
second-generation TKIs or HSCT are recommended when
imatinib intolerance or resistance occurs [7]. However,
these treatment alterations may adversely affect therapeutic
outcomes [8], and the long-term effectiveness of changing
therapeutic schedules is still inconclusive [12].
This study indicates that 26.9 % of patients showed poor
adherence to imatinib, this finding is consistent with pre-
vious research suggesting that the proportion of poor
adherence to imatinib is between 26.4 and 36.1 % [11, 13].
In contrast to the mean MPR ranging from 77.7 to 95.3 %
in previous studies [10, 11, 13], the median MPR of this
study was 98.3 % (mean 89.7 %). This can be explained by
the different study population, sample size and most
importantly, the adherence measures.
Currently, there is no generally accepted gold standard
for measuring adherence [22] since there is no direct
method of measuring imatinib or its metabolites’ levels
Patient years

















Adherence: 4 years, 91%
Non-adherence: 4 years, 72%
Log-rank test, p=0.0076
Adherence* 81/84 78/81 77/78 77/77 77/77
Non-adherence* 31/32 28/31 24/28 23/24 24/24
Fig. 4 Kaplan–Meier survival
curves comparing the




ratio (MPR) [ 90 %; non-
adherence: patients’
MPR B 90 %. * Numerator:
number of patients survived in
the patient-year; Denominator:
number of patients contributing
to the patient-year
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[12]. So far self-reported measures (e.g. visual analogue
scale) [13], Basel Assessment of Adherence Scale [13] and
pill count [23] have been found to either over- [24] or
under-estimated poor adherence [11, 23, 25, 26]. Patients’
MPR derived from dispensing data for reimbursement
purpose has been used to measure adherence under the
assumption that patients take medication as dispensed.
However, previous studies for assessing imatinib adher-
ence using medical claims data [10, 14] have been limited
to chronic phase CML patients using imatinib as the first-
line therapy for less than 2 years [11], yet only short-term
molecular responses instead of long-term disease progres-
sion [11, 12] or survival rates [11, 13] were evaluated.
Although our study has found that patients achieving the
therapeutic targets at the beginning of imatinib therapy (the
3rd or 6th month) are likely to achieve the completed
therapeutic responses at the 18th month, however a
minority of patients could not achieve the therapeutic target
(3.4 %). In addition, the proportion of patients achieving
CCyR at the 12th month in our study was lower (65 %)
compared to previous randomised controlled trials in which
either chronic phase patients (69 %) [27] or a higher dose
(70 % of started with 800 mg daily) of imatinib (75 %)
[28] were involved.
Although a conventional cut-off of 90 % MPR was used
in most literature as a proxy to measure adherence of i-
matinib users [11], various definitions were used to assess
MPR, and the clinical implication of adherence defined by
this measure is still controversial. Using the sensitivity
analysis, we found that MPRs at more than 80, 85 and
90 % was associated with achieving CCyR and MMR at
the 18th month and a lower mortality risk. However, when
the cut-off point of MPR reached 95 %, then adherence
was not associated with any benefit on the proportion of
patients achieving clinical outcome indicators. This indi-
cates that an MPR at 95 % may be the ceiling for optimal
adherence.
This study longitudinally retrieved details of patients
with various disease conditions and previous treatments
from medical charts for further analysis, and found direct
association between adherence to imatinib and long-term
survival rate. However, as this study only included patients
Clinical responses OR(d) (95%CI) P value OR / HR (95%CI)
Achieved CCyR(a) at 18th month (n=87)
MPR(f) 5.2 (0.8, 39.6) 0.0765
MPR 90% vs. MPR<90% 11.6 (1.7, 114.7) 0.0131*
11.9 (1.7, 113.3) 0.0140*
95% vs. MPR<95%
MPR 85% vs. MPR<85%
MPR 80% vs. MPR<80% 13.2 (1.9, 122.6) 0.0102*
Achieved MMR(b) at 18 month (n=74)
MPR 95% vs. MPR<95% 1.5 (0.4, 6.1) 0.5908
5.1 (1.1, 26.8) 0.0351*
6.8 (1.2, 45.4) 0.0281*
MPR 90% vs. MPR<90%
MPR 85% vs. MPR<85%
MPR 80% vs. MPR<80% 8.8 (1.5, 63.9) 0.0151*
Achieved CMR(c) at 18 month (n=74)
MPR 95% vs. MPR<95% 0.7 (0.2, 2.3) 0.5196
1.2 (0.3, 5.2) 0.7623
2.1 (0.4, 12.6) 0.3740
MPR 90% vs. MPR<90%
MPR 85% vs. MPR<85%
MPR 80% vs. MPR<80% 3.2 (0.6, 25.8) 0.1873
Mortality rate (n=116) HR(e) (95%CI) P value
MPR 95% vs. MPR<95% 0.1 (0.01, 0.6) 0.0118*
0.1 (0.01, 0.6) 0.0118*
0.3 (0.06, 1.3) 0.1116
MPR 90% vs. MPR<90%
MPR 85% vs. MPR<85%
MPR 80% vs. MPR<80% 0.3 (0.06, 1.3) 0.1116
Favor adherence Favor non-adherence
Favor non-adherence Favor adherence
Favor non-adherence Favor adherence
Favor non-adherence Favor adherence
Fig. 5 Sensitivity analysis for
the influences of various
medication possession ratio cut-





response. (d)OR odds ratio. (e)HR
hazard ratio. (f)MPR medication
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confidence interval
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from one centre, the results cannot be generalised to a
wider population due to its limited sample size. It also
assumed that the dispensing records represented actual
consumption and therefore, MPR may have over-estimated
imatinib adherence. In addition, for those who had swit-
ched to second generation TKIs, the imatinib MPR might
be relatively lower. During the study period, 26 patients
were found to have missed the follow-up appointments.
Consequently, they were not included in the analysis of
clinical indicators measured at the 18th month of imatinib
treatment, and thus the assessment of adherence-related
clinical outcomes might be biased. Relevant covariates
were included in the regression analysis, although other
confounding factors or indication bias may have influenced
the results. The comparatively small number of outcomes
(deaths) also resulted in relatively wide confidence inter-
vals for the estimate of the strength of association.
Conclusions
This retrospective, single-centre study has revealed that
most of the Asian CML patients were generally well
adherent to imatinib treatment despite a minority of them
having experienced repeat interruptions. Imatinib adher-
ence is associated with improvement in certain short-term
clinical indicators and survival. Further research is needed
to validate the adherence measures, to explore the patient
and healthcare provider related factors on adherence and
evaluate the clinical outcomes for patients switching from
imatinib to second generation TKIs in clinical practice.
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